Prof. Dr. Ahmet Sezer

Больница Medical Park Seyhan — медицинская онкология

Рак легкого

Рак молочной железы

Рак головы и шеи

Опухоли мягких тканей

Иммунотерапия

Таргетная лекарственная терапия

Химиотерапия

Поддерживающая терапия

Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592–604. DOI: 10.1016/S0140-6736(21)00228-2. PMID: 33581821.

Pérol M, Yoshida T, Ahn MJ, et al. Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2026 Oct 24. Online ahead of print. DOI: 10.1056/NEJMoa2609482. PMID: 42929702.

Sezer A, Sumbul AT, Abali H. Is it rational to continue anti-neoplastics with minimal toxicity even after progression in patients with no other options? Possibly yes. Asian Pac J Cancer Prev. 2014;15(2):1061–1062. DOI: 10.7314/apjcp.2014.15.2.1061. PMID: 24568451.

Gandara DR, Makharadze T, Gümüş M, et al. Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy. Cancers (Basel). 2026;18(6):916. DOI: 10.3390/cancers18060916. PMID: 41899521.

Gandara D, Gogishvili M, Sezer A, et al. Composite patient-reported outcomes and risk prediction for overall survival in advanced non-small cell lung cancer with first-line cemiplimab. Front Oncol. 2026;16:1676687. DOI: 10.3389/fonc.2026.1676687. PMID: 41821892.

Sezer A, Akkus B, Guler OC, Onal HC, Sumbul AT. Concurrent versus sandwich treatment in adjuvant treatment in high risk operated gastric cancer: A single center experience. J BUON. 2020;25(5):2341–2349. PMID: 33277854.